Antibody responses to inactivated SARS‐CoV‐2 vaccine in peritoneal dialysis patients

Abstract

Introduction As end‐stage renal disease (ESRD) patients generally have reduced responses to the vaccines, effectiveness of newly developed SARS‐CoV‐2 vaccines in ESRD are also matters of curiosity. We aimed to investigate the humoral responses of our peritoneal dialysis (PD) patients to the inactivated SARS‐CoV‐2 vaccine. Methods Humoral immune responses of 23 PD patients who received two doses of the inactivated SARS‐CoV‐2 vaccine were investigated with a commercial test that measures IgG antibodies towards receptor binding domain of SARS‐CoV‐2 spike protein. Seropositivity rates, antibody titers, and ESRD related clinical data were compared with 51 hemodialysis (HD) patients and 29 healthy volunteers. Results Seropositivity of PD patients with the inactivated vaccine was 95.6%. Both the rate of seropositivity and SARS‐CoV‐2 IgG antibody levels in PD patients were not different from the healthy controls (p = 0.85 and 0.19, respectively). While seropositivity rates were not different for PD or HD patients (p = 0.09), the magnitude of humoral responses was significantly higher in PD patients (p = 0.0001). There were no vaccine‐related serious adverse events. In the 3‐months clinical follow‐up, none of the patients experienced SARS‐CoV‐2 infection. Conclusion Two doses of the inactivated vaccine generate adequate humoral immune response in PD patients without any serious adverse events.

WITHDRAWN: Antibody responses 8-20 weeks after two doses of SARS-CoV-2 vaccine (CoronaVac) in hemodialysis patients: Results of a single center in northeast Turkey

“…In HD patients, the weakening of innate and adaptive immune systems functions due to the decrease in both skewed Th1/Th2 T-cell ratios and dendritic and T-cell cells increase the tendency to infections. Therefore, it is important to determine the periodic intervals of additional doses by determining the antibody levels of these patients during the ongoing pandemic process [3,10,11].In recent studies in HD patients, the antibody level was 80% after two doses of SARS-CoV-2 inactivated vaccine, while the Serologic response in HD patients with mRNA vaccine was approximate90% [12,13] .These results are one month after the second dose of vaccine. Presumably, these levels may decrease as the antibody levels are checked again in the following weeks.…”

Waning of SARS-CoV-2 Vaccine-Induced Immune Response over 6 Months in Peritoneal Dialysis Patients and the Role of a Booster Dose in Maintaining Seropositivity

“…In a previous study, the initial seroconversion rate of PD patients with inactivated vaccine was not different from healthy controls [ 13 ]. However, in this comparison over 6 months of time without a booster dose, we found that maintenance of seropositivity was significantly lower in PD patients than healthy controls (44% vs. 88%).…”

“…PD and HD patients might have different immune profiles. Some previous SARS-CoV-2 vaccine studies showed higher initial immunogenicity in PD patients [ 10 , 13 ]. However, with this study, we found similar antibody levels and seropositivity rates for PD and HD patients 6 months after initial vaccinations.…”

Long‐term antibody response following COVID‐19 vaccination in patients receiving peritoneal dialysis

“… 1 , 2 Murt et al showed that 95.6% of PD patients developed SARS‐CoV‐2 IgG seropositivity 3–4 weeks following two doses of inactivated SARS‐CoV‐2 vaccine (CoronaVac, developed by Sinovac Life Sciences). 3 Sustained antibody responses 6 months following two doses of BNT162b2 were recently reported in a cohort of 64 PD patients. 4 A UK study involving hemodialysis patients showed differential early immune response to BNT162b2 and AZD1222 vaccines with the latter inducing suboptimal neutralizing antibody levels.…”